2 Drug Stocks Selling Off on Failed Studies

AQXP and SMMT are both bracing for a double-digit percentage drop at the open

Jun 27, 2018 at 9:23 AM
facebook X logo linkedin


Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) is bracing for a steep plunge out of the gate, after the company said it would stop developing its bladder pain treatment, rosiptor, following disappointing late-stage study data for the lead drug. The firm also said it is evaluating its current drug pipeline, and looking into strategic alternatives.

At last check, AQXP stock was down 82.2% in pre-market trading -- on track to open at its lowest point since August 2015. Last night, the stock closed at $15.31, up 30% on the year. However, short sellers have been actively betting against a pullback, with short interest on Aquinox Pharmaceuticals stock surging 34.4% in the most recent reporting period. These bearish bettors are sure to be sidelined today, with the security likely headed to the short-sale restricted list.

Skepticism has ramped up in the options pits, too, with speculators at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) buying to open 2.91 puts for each call in the past 10 days. The July 5 strike is home to peak front-month put open interest, and those who purchased the puts could be staring at a handsome profit should today's pre-market price action pan out.

Summit Therapeutics PLC (NASDAQ:SMMT) has halted the development of its Duchenne muscular dystrophy (DMD) drug after it failed in a mid-stage trial. As a result, SMMT stock is down 79% ahead of the bell, set to open at its lowest point on record.

Heading into today's trading, SMMT shares were up 14% year-to-date, and closed last night at $12.65. A round of bearish brokerage notes could come down the pike, too, considering all six analysts covering the stock currently maintain a "buy" or better rating, and the average 12-month price target sits all the way up at $28.63.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI